Congenital TORCH Infections Carry a Markedly Higher Neurodevelopmental Risk
Rare infections passed from a pregnant woman to the fetus are linked to a sharply higher likelihood of autism and intellectual disability later in childhood, based on a Swedish registry study published in JAMA Pediatrics. The cohort was enormous by pediatric epidemiology standards: 3.7 million people born in Sweden between 1987 and 2021, followed through health and education records for up to three decades. Among them, 975 had a diagnosed congenital TORCH infection, the group of pathogens that includes cytomegalovirus, rubella, toxoplasma, and herpesvirus.
The signal was strongest for the most severe developmental outcomes. Children with a congenital TORCH infection were about three times more likely to be diagnosed with autism than children without such an infection, more than seven times more likely to receive an intellectual disability diagnosis, and up to 30 times more likely to have severe to profound intellectual disability. Those are large relative risks, but the underlying exposure was rare, which keeps the population-level burden small.
Why a Rare Exposure Still Matters in Prenatal Care
Congenital infections occupy a narrow but clinically important corner of prenatal medicine because they can alter brain development during a period when fetal neural circuits are still forming. Placental transmission is uncommon, and most routine infections in pregnancy do not reach the fetus. TORCH pathogens are different. They can cross the placenta, establish congenital infection, and interfere with neurologic development in ways that may not become fully visible until speech, learning, and social communication milestones start to diverge.
Reneé Gardner, a researcher at Karolinska Institutet, emphasized that these infections account for only a very small proportion of autism cases in the population. The individual risk, however, is unmistakably elevated in exposed children. In practical terms, that means the findings do not explain most autism diagnoses, but they do point to a biologically plausible preventable pathway for a small number of affected families.
One estimate from the study placed the attributable fraction at about 1.2 percent of severe intellectual disability cases in Sweden and about 0.034 percent of autism cases. Even with low attributable fractions, prevention still carries weight because the upstream event may be avoidable through vaccination, infection control, and prenatal surveillance.
The Study Design Strengthens the Association
The analysis drew on national register data, which reduced the usual limitations of small case series and referral-based cohorts. Hugo Sjöqvist, the study’s lead author and a PhD student at Karolinska Institutet, said earlier research had established a link between congenital infection and intellectual disability, but the autism association had remained less certain because much of the literature came from small patient groups.
Here, the scale changed the evidentiary threshold. Investigators not only tracked diagnoses of autism and intellectual disability, they also examined educational outcomes. Even among children who did not receive either diagnosis, those with congenital TORCH infection had lower average grades than peers without infection. Lower school performance in the absence of a formal neurodevelopmental diagnosis suggests that the effects may extend beyond the conditions counted in administrative records.
A sibling comparison added another layer of confidence. Children with congenital TORCH infection were compared with their own siblings who had not been infected. The pattern remained similar, which argues against shared family characteristics as the main explanation. In epidemiologic terms, that does not prove causality, but it reduces the odds that the association is simply a byproduct of the home environment, genetics shared across siblings, or other family-level confounders.
Severe Intellectual Disability Drove the Largest Risk Difference
The most striking divergence appeared at the severe end of the spectrum. Severe to profound intellectual disability rose as much as 30-fold among children with congenital TORCH infection. Such an extreme gradient is consistent with early developmental injury during organogenesis and ongoing brain maturation, when viral damage, inflammatory cascades, and disrupted cellular development can have lasting consequences.
A brief sentence belongs here: the heaviest neurologic burden fell on the smallest exposed group.
That pattern matters clinically because severe developmental impairment often creates the greatest need for long-term educational support, rehabilitation services, and family resources. Earlier recognition of congenital infection could therefore influence not only surveillance for autism and learning problems, but also planning for developmental intervention and school-based accommodations.
Prevention Remains the Most Actionable Point
Reneé Gardner said the findings reinforce the importance of preventing infections that can be transmitted to the fetus during pregnancy. Rubella offers the clearest example. In Sweden, it has virtually disappeared since national vaccination programs were introduced. That public health success illustrates what prevention can do when a congenital infection is blocked before pregnancy or early enough in gestation to avoid fetal exposure.
The same logic applies across the TORCH group. Not every pathogen in the category is vaccine-preventable, but several are modifiable through vaccination, hygiene, food safety, exposure reduction, and prenatal care. Because the infections are rare, the opportunity lies less in changing population-wide autism rates than in preventing catastrophic outcomes in the small number of pregnancies affected.
What the Data Do Not Show
The study did not identify clear links between congenital TORCH infections and other neuropsychiatric conditions, including ADHD or obsessive-compulsive disorder. That is a useful negative finding. It suggests the strongest association sits with core neurodevelopmental outcomes rather than a broad, nonspecific increase across all behavioral diagnoses.
The analysis also remains observational. A registry study of this size can define risk patterns with unusual clarity, but it cannot fully disentangle every biological and social factor that influences neurodevelopment. The rarity of congenital TORCH infection is another constraint: despite the striking relative risks, the absolute number of affected children remains small.
Even so, the core clinical message is direct. When TORCH infection reaches the fetus, the neurologic stakes can be substantial, and the downstream effects may persist for years. For prenatal medicine, that shifts these infections from uncommon curiosities to preventable causes of severe developmental injury.
The clearest next step is not speculation about a broad autism epidemic. It is maintaining rubella vaccination, strengthening pregnancy infection prevention, and improving recognition of congenital infections that can be detected and managed early enough to matter.